Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2025

Accounting Policies [Abstract]

Schedule of Potentially Dilutive Securities Not Considered for Calculation of Diluted Net Loss Per Share

Potentially dilutive securities not considered for the calculation of diluted net loss per share are as follows (in common stock equivalents):

	March 31,
	2025		2024
Common stock warrants		—		5,864
Common stock options and restricted stock units		9,420,566		5,712,725
Employee stock purchase plan		34,143		41,862
Total		9,454,709		5,760,451

Summary of Significant Expense Categories Reviewed by CODM

The table below summarizes the significant expense categories regularly reviewed by our CODM for the three months ended March 31, 2025 and 2024.

	March 31,
	2025		2024
License and collaboration agreement revenues	$	—	$	235
Research and development expenses:
Efzofitimod expenses		8,804		10,965
Preclinical development and other shared research and development expenses		2,560		2,073
Non-cash expenses (depreciation and stock-based compensation)		450		326
Total research and development expenses		11,814		13,364
General and administrative expenses:
Other general and administrative expenses		3,064		2,915
Non-cash expenses (depreciation and stock-based compensation)		895		592
Total general and administrative expenses		3,959		3,507
Other segment items (1)		892		1,149
Consolidated net loss	$	14,881	$	15,487
(1) Other segment items included interest income and interest expense.